Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Update on EU-funded Nipah virus vaccine project

By HC Andersen Capital
ExpreS2ion Biotech Holding

On 1 December 2023, ExpreS2ion Biotechnologies announced the award of a grant that amounts to EUR 8m (approx. SEK 90m) for the VICI-Disease consortium. 53% of the amount is a direct contribution to ExpreS2ion’s part of the project costs. The development project aims to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate. This is the first strong signal of ExpreS2ion’s new strategy direction, leveraging the platform to advance assets with shorter development timelines and less costs to value creation.

ExpreS2ion Biotechnologies’ CEO Bent Frandsen will dig a bit deeper into the news about the Nipah virus vaccine project on 14 December 2023 at 10:00 in a virtual live event.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 15:03 8/12-2023.

Recent videos

Rapala H2'25: North American sales a highlight of the end of the year
12.03.2026 klo 17.25 Rapala VMC
Columbus – Presentation of Annual Report 2025
12.03.2026 klo 14.00 Columbus
Tokmanni Q4’25: Dollarstore’s turnaround is stalling
12.03.2026 klo 13.02 Tokmanni Group
Multitude, Webcast, Q4'25
12.03.2026 klo 11.00 Multitude
Rapala VMC Oyj, Audiocast, Q4'25
12.03.2026 klo 11.00 Rapala VMC
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.